Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody

被引:45
作者
Sánchez-Martínez, S
Lorizate, M
Katinger, H
Kunert, R
Basañez, G
Nieva, JL
机构
[1] Euskal Herriko Unibertsitatea, CSIC, Biofis Unitatea, Bilbao 48080, Spain
[2] Euskal Herriko Unibertsitatea, Biokim Saila, Bilbao 48080, Spain
[3] Agr Univ Vienna, Inst Appl Microbiol, A-1190 Vienna, Austria
关键词
HIV-1; gp41; neutralization; Mab2F5; cardiolipin; antiphospholipid antibody;
D O I
10.1016/j.febslet.2006.03.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV-1 neutralizing monoclonal antibody (Mab) 2175 recognizes a membrane-partitioning gp41 sequence. Just recently its capacity to react with cardiolipin has been demonstrated. Here, we have studied the specificity of Mab2F5-phospholipid interactions comparing partitioning into lipid bilayers with recognition of molecular species dispersed in solution. Using a liposome-based ELISA we demonstrate a preferential association with cardiolipin bilayers. When different soluble lysoderivatives were compared in their capacity to inhibit Mab2F5 binding to immobilized HIV-1 peptide epitope, only dilysocardiolipin resulted effective in blocking the process. Dilyso-cardiolipin also competed with native-functional gp41 for 2F5 recognition. Thus, our data support specific cardiolipin recognition by 2F5 that is not dependent on lipid bilayer assembly and involves the epitope-binding site. These findings might be of relevance for understanding the molecular basis of HIV-1 immune evasion. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:2395 / 2399
页数:5
相关论文
共 27 条
[1]   Structural analysis of the epitope of the Anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion [J].
Barbato, G ;
Bianchi, E ;
Ingallinella, P ;
Hurni, WH ;
Miller, MD ;
Cilibertol, G ;
Cortese, R ;
Bazzo, R ;
Shiver, JW ;
Pessi, A .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 330 (05) :1101-1115
[2]   GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION [J].
BUCHACHER, A ;
PREDL, R ;
STRUTZENBERGER, K ;
STEINFELLNER, W ;
TRKOLA, A ;
PURTSCHER, M ;
GRUBER, G ;
TAUER, C ;
STEINDL, F ;
JUNGBAUER, A ;
KATINGER, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :359-369
[3]   NEUTRALIZATION OF DIVERGENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS AND PRIMARY ISOLATES BY IAM-41-2F5, AN ANTI-GP41 HUMAN MONOCLONAL-ANTIBODY [J].
CONLEY, AJ ;
KESSLER, JA ;
BOOTS, LJ ;
TUNG, JS ;
ARNOLD, BA ;
KELLER, PM ;
SHAW, AR ;
EMINI, EA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) :3348-3352
[4]   Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease [J].
Douvas, A ;
Takehana, Y ;
Ehresmann, G ;
Chernyovskiy, T ;
Daar, ES .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (16) :1509-1517
[5]   Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death [J].
Esposti, MD ;
Cristea, IM ;
Gaskell, SJ ;
Nakao, Y ;
Dive, C .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (12) :1300-1309
[6]   Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections [J].
Guglielmone, H ;
Vitozzi, S ;
Elbarcha, O ;
Fernandez, E .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (05) :500-504
[7]   Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies [J].
Haynes, BF ;
Fleming, J ;
St Clair, EW ;
Katinger, H ;
Stiegler, G ;
Kunert, R ;
Robinson, J ;
Scearce, RM ;
Plonk, K ;
Staats, HF ;
Ortel, TL ;
Liao, HX ;
Alam, SM .
SCIENCE, 2005, 308 (5730) :1906-1908
[8]   Molecular characterization of five neutralizing anti-HIV type 1 antibodies:: Identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5 [J].
Kunert, R ;
Rüker, F ;
Katinger, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (13) :1115-1128
[9]  
Kunert R, 2000, BIOTECHNOL BIOENG, V67, P97, DOI 10.1002/(SICI)1097-0290(20000105)67:1<97::AID-BIT11>3.0.CO
[10]  
2-2